Terahara K, Sato T, Adachi Y, Tonouchi K, Onodera T, Moriyama S
iScience. 2022; 25(9):104959.
PMID: 35992306
PMC: 9384329.
DOI: 10.1016/j.isci.2022.104959.
Hu R, Hotta M, Maruyama T, Fujisawa M, Sou K, Takeoka S
ACS Omega. 2022; 7(30):26936-26944.
PMID: 35915635
PMC: 9328125.
DOI: 10.1021/acsomega.2c03597.
Zhuang S, Tang L, Dai Y, Feng X, Fang Y, Tang H
PeerJ. 2021; 9:e11232.
PMID: 33889450
PMC: 8038641.
DOI: 10.7717/peerj.11232.
Uemura K, Sasaki M, Sanaki T, Toba S, Takahashi Y, Orba Y
Sci Rep. 2021; 11(1):5376.
PMID: 33686154
PMC: 7940632.
DOI: 10.1038/s41598-021-84882-7.
Aoki K, Nagasawa T, Ishii Y, Yagi S, Kashiwagi K, Miyazaki T
J Infect Chemother. 2021; 27(2):319-322.
PMID: 33388232
PMC: 7757343.
DOI: 10.1016/j.jiac.2020.11.015.
The contribution of the cytoplasmic retrieval signal of severe acute respiratory syndrome coronavirus to intracellular accumulation of S proteins and incorporation of S protein into virus-like particles.
Ujike M, Huang C, Shirato K, Makino S, Taguchi F
J Gen Virol. 2016; 97(8):1853-1864.
PMID: 27145752
PMC: 5764123.
DOI: 10.1099/jgv.0.000494.
Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response.
Glowacka I, Bertram S, Muller M, Allen P, Soilleux E, Pfefferle S
J Virol. 2011; 85(9):4122-34.
PMID: 21325420
PMC: 3126222.
DOI: 10.1128/JVI.02232-10.
Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.
Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F
J Virol. 2010; 84(24):12658-64.
PMID: 20926566
PMC: 3004351.
DOI: 10.1128/JVI.01542-10.
Severe acute respiratory syndrome (SARS).
Cleri D, Ricketti A, Vernaleo J
Infect Dis Clin North Am. 2010; 24(1):175-202.
PMID: 20171552
PMC: 7135483.
DOI: 10.1016/j.idc.2009.10.005.
Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
Ishii K, Hasegawa H, Nagata N, Ami Y, Fukushi S, Taguchi F
Microbiol Immunol. 2009; 53(2):75-82.
PMID: 19291090
PMC: 7168451.
DOI: 10.1111/j.1348-0421.2008.00097.x.
Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen.
Tsunetsugu-Yokota Y
Methods Mol Biol. 2008; 454:119-26.
PMID: 19057880
PMC: 7122600.
DOI: 10.1007/978-1-59745-181-9_11.
Establishment and characterization of monoclonal antibodies against SARS coronavirus.
Ohnishi K
Methods Mol Biol. 2008; 454:191-203.
PMID: 19057876
PMC: 7120479.
DOI: 10.1007/978-1-59745-181-9_15.
A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV.
Mitsuki Y, Ohnishi K, Takagi H, Oshima M, Yamamoto T, Mizukoshi F
Microbes Infect. 2008; 10(8):908-15.
PMID: 18606245
PMC: 7110505.
DOI: 10.1016/j.micinf.2008.05.009.
Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice.
Nagata N, Iwata N, Hasegawa H, Fukushi S, Harashima A, Sato Y
Am J Pathol. 2008; 172(6):1625-37.
PMID: 18467696
PMC: 2408422.
DOI: 10.2353/ajpath.2008.071060.
Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes.
Nagata N, Iwata N, Hasegawa H, Sato Y, Morikawa S, Saijo M
Int J Exp Pathol. 2007; 88(6):403-14.
PMID: 18039277
PMC: 2517337.
DOI: 10.1111/j.1365-2613.2007.00567.x.
Highly attenuated vaccinia virus DIs as a potential SARS vaccine.
Ishii K, Hasegawa H, Nagata N, Mizutani T, Morikawa S, Tashiro M
Adv Exp Med Biol. 2006; 581:593-6.
PMID: 17037603
PMC: 7123757.
DOI: 10.1007/978-0-387-33012-9_107.
Production and characterization of monoclonal antibodies against the nucleocapsid protein of SARS-CoV.
Fang Y, Pekosz A, Haynes L, Nelson E, Rowland R
Adv Exp Med Biol. 2006; 581:153-6.
PMID: 17037523
PMC: 7139450.
DOI: 10.1007/978-0-387-33012-9_27.
Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs.
Ishii K, Hasegawa H, Nagata N, Mizutani T, Morikawa S, Suzuki T
Virology. 2006; 351(2):368-80.
PMID: 16678878
PMC: 7111839.
DOI: 10.1016/j.virol.2006.03.020.
Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
Tsunetsugu-Yokota Y, Ohnishi K, Takemori T
Rev Med Virol. 2006; 16(2):117-31.
PMID: 16518829
PMC: 7169118.
DOI: 10.1002/rmv.492.